Aortitis accelerates the growth rate of thoracic aortic aneurysms Authors: Antoine Benichou, Marie De Gaulmyn, Guillaume Guimbretiere, Claire Toquet, Jean-Michel Serfaty, Levana Samoul, Jean-Christian Roussel, Alexis F Guedon, Loubna Dari, Christian Agard, Marie Morard, Olivier Espitia Published: 2026 ABSTRACT AbstractBackgroundThoracic aortic aneurysms (TAA) are predominantly degenerative. Non-infectious inflammatory aortitis, including giant cell arteritis (GCA), Takayasu arteritis and clinically isolated aortitis (CIA), represents a less understood aetiology with poorly characterised growth patterns. While GCA is linked to higher TAA risk, preoperative growth data for inflammatory TAA are scarce. This study compares growth rates in histologically proven inflammatory aortitis.MethodsWe conducted a retrospective case–control study, including patients with histologically proven aortitis and matched controls with degenerative TAA. Cases and controls were matched for age, sex, surgical year and procedure type. Aneurysm growth rate (mm/month) was calculated from serial imaging.ResultsThis study included 23 patients with histologically confirmed aortitis (13 GCA, 9 CIA) and 42 matched controls with degenerative TAA. The mean growth rate was significantly higher in the aortitis group (0.177±0.01 mm/month; 2.12 mm/year) compared with controls (0.039±0.02 mm/month; 0.47 mm/year), representing a 4.5-fold acceleration (p<0.001). Among inflammatory etiologies, CIA demonstrated faster growth (0.338±0.06 mm/month; 4.06 mm/year) than GCA (2.1 mm/year; p<0.01). Patients with CIA more frequently required Bentall procedures (33% vs 0%, p=0.047). No differences were observed in baseline demographics, cardiovascular risk factors or baseline aortic diameters between groups. Histologically, 70% of aortitis cases exhibited granulomatous inflammation.ConclusionInflammatory aortitis is associated with a 4.5-fold faster preoperative TAA growth rate compared with degenerative aneurysms, with CIA exhibiting two times the growth rate of GCA. Prospective studies are warranted to validate these results and optimise surveillance and management strategies for this high-risk population. WHAT IS ALREADY KNOWN ON THIS TOPIC Thoracic aortic aneurysms (TAA) are primarily degenerative, but non-infectious inflammatory aortitis—including giant cell arteritis (GCA) and clinically isolated aortitis (CIA)—is a less understood aetiology. GCA is known to increase TAA risk 17-fold, yet preoperative growth data for inflammatory TAA remain scarce and unmatched. Previous studies suggested faster growth in CIA and GCA, but lacked rigorous control comparisons or focused only on specific subtypes. Thoracic aortic aneurysms (TAA) are primarily degenerative, but non-infectious inflammatory aortitis—including giant cell arteritis (GCA) and clinically isolated aortitis (CIA)—is a less understood aetiology. GCA is known to increase TAA risk 17-fold, yet preoperative growth data for inflammatory TAA remain scarce and unmatched. Previous studies suggested faster growth in CIA and GCA, but lacked rigorous control comparisons or focused only on specific subtypes. WHAT THIS STUDY ADDS This matched case–control study demonstrates that inflammatory aortitis accelerates TAA growth 4.5-fold compared with degenerative aneurysms (2.12 vs 0.47 mm/year), with CIA growing two times as fast as GCA (4.06 vs 2.1 mm/year). It is the first to directly compare preoperative growth rates using matched controls, revealing CIA as the fastest non-infectious cause of TAA progression documented. This matched case–control study demonstrates that inflammatory aortitis accelerates TAA growth 4.5-fold compared with degenerative aneurysms (2.12 vs 0.47 mm/year), with CIA growing two times as fast as GCA (4.06 vs 2.1 mm/year). It is the first to directly compare preoperative growth rates using matched controls, revealing CIA as the fastest non-infectious cause of TAA progression documented. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings underscore the need for heightened clinical suspicion of inflammatory aortitis in patients with rapid TAA growth, even without classic symptoms or biomarkers. Prospective studies are warranted to validate these results and optimise surveillance and management, particularly for CIA, which may require more intensive postoperative monitoring and potential empiric immunosuppression. These findings underscore the need for heightened clinical suspicion of inflammatory aortitis in patients with rapid TAA growth, even without classic symptoms or biomarkers. Prospective studies are warranted to validate these results and optimise surveillance and management, particularly for CIA, which may require more intensive postoperative monitoring and potential empiric immunosuppression. Introduction Thoracic aortic aneurysms (TAA) represent a serious cardiovascular condition with significant morbidity and mortality. While degenerative atherosclerotic processes account for the majority of TAA cases, non-infectious aortitis constitutes an important subset of aetiologies that remains incompletely characterised. Aortitis encompasses several forms of large vessel vasculitis (LVV), including giant cell arteritis (GCA), Takayasu arteritis and clinically isolated aortitis (CIA), all characterised by inflammatory infiltration of the aortic wall. The pathophysiology of aneurysm formation in inflammatory aortitis differs fundamentally from degenerative processes. In GCA, the most common LVV in Western populations, inflammatory cell infiltration leads to destruction of elastic fibres through metalloprotease activity, depletion of smooth muscle cells via apoptosis and replacement with disorganised fibrous tissue.1 These structural alterations could promote more rapid aneurysmal expansion compared with atherosclerotic degeneration. Previous epidemiological studies have demonstrated that patients with GCA face a 17-fold increased risk of developing TAA compared with the general population, with complications occurring throughout the disease course at rates of 30.5 per 1000 patient-years.2 3 However, data regarding the preoperative growth rate of inflammatory TAA remain surprisingly limited. A 2018 study reported an average growth rate of 1.3 mm/year in GCA-associated TAA without a control comparison,4 while a 2020 study suggested a non-significant trend towards faster growth in CIA (2.9 mm/year) versus unmatched controls (−1.6 mm/year).5 Furthermore, preoperative identification of patients with TAA secondary to CIA remains challenging, as these patients typically remain asymptomatic. Notably, postoperative outcomes in patients with CIA appear less favourable compared with those with non-inflammatory TAA.6 7 Understanding the natural history and growth kinetics of inflammatory TAA is crucial for developing optimal surveillance strategies and determining appropriate surgical timing. The aim of this study was to compare preoperative aneurysm growth rates between patients with histologically proven inflammatory aortitis and matched controls with degenerative TAA and to compare growth rates according to CIA or GCA aetiology. Patients and methods Study design and population We conducted a retrospective, monocentric, case–control study at Nantes University Hospital, France, including all patients with histologically proven aortitis between January 1997 and February 2024. Cases were defined as adult patients (≥18 years) with non-infectious inflammatory aortitis histologically confirmed according to consensus criteria, requiring inflammatory infiltrate involving the media and/or intima.8 Each aortic histology was reviewed by a specialist in cardiovascular pathology (CT). Exclusion criteria comprised infectious aortitis, hereditary aneurysm syndromes (Marfan syndrome, Ehlers-Danlos syndrome, etc), bicuspid aortic valve disease, non-inflammatory histology, isolated periaortitis or mediastinal tumour invasion. Finally, aortitis cases were included in the analysis if at least one matched control could be identified as described below. To assess aneurysm growth rate, we included patients who had undergone at least two measurements of maximal thoracic aortic diameter at minimum 3-month intervals using validated imaging modalities: CT angiography (CTA), MRI or transthoracic echocardiography. Aortitis classification GCA was diagnosed according to the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology classification criteria.9 Takayasu arteritis was diagnosed according to ACR criteria10 and/or modified Ishikawa criteria.11 CIA was defined as a histologically proven aortitis without an increase in biological inflammatory markers before or after aortic surgery, with no other vascular abnormalities evident on histological or imaging tests, with the absence of any identifiable underlying inflammatory disease, in accordance with the 2012 revised Chapel Hill Consensus Conference Nomenclature, which classifies CIA as a single-organ vasculitis.12 CIA is therefore a clinical, exclusion-based diagnosis that may share overlapping histopathological features with GCA, notably granulomatous inflammation with giant cells. Histological classification distinguished granulomatous aortitis (presence of epithelioid macrophages, giant cells and granulomas) from lymphoplasmacytic aortitis (absence of granulomas with abundant mononuclear lymphoplasmacytic infiltrate). Control selection Control subjects were identified from the cardiac surgery database (Cordabase) at Nantes University Hospital, France, between January 2010 and March 2024. Controls were matched 1:1 to 1:4 with cases for age at surgery, sex, surgical year and surgical procedure type. Control inclusion criteria required: (1) no genetic syndrome or bicuspid valve-related aneurysm; (2) at least two aortic diameter measurements at minimum 3-month intervals preoperatively; (3) appropriate matching parameters. Data collection We retrospectively collected comprehensive clinical data from electronic medical records, including demographic characteristics, cardiovascular risk factors (hypertension, dyslipidaemia, diabetes, obesity, smoking status), personal and family cardiovascular history, aortic aneurysm topography, surgical details, histological findings and preoperative treatments (corticosteroids, immunosuppressants, antiplatelet agents and statins). C reactive protein (CRP) measured within 3 months preoperatively was recorded when available, with inflammatory syndrome defined as CRP>10 mg/L. Aortic diameter measurement When CT images were available, aortic diameters were centrally reviewed (AB and MDG). Measurements of maximal diameters were performed at the level of (1) the sinuses of Valsalva, (2) the sinotubular junction, (3) the ascending aorta, (4) the aortic arch and (5) the descending aorta posterior to the left atrium, perpendicular to the aortic axis at maximal diameter. When images were unavailable, diameters from official radiology reports were used. Growth rate calculation Aneurysm growth rate (mm/month) was calculated as: Growth rate = (D_max − D_baseline)/time interval (months). D_max represents the preoperative diameter and D_baseline represents the earliest measurement. Statistical analysis Continuous variables were expressed as means with SD or medians with IQRs 25–75 (Q1–Q3). Quantitative variables were compared using Student’s t-test for normally distributed data or Wilcoxon rank-sum test otherwise. Qualitative variables were compared using Fisher’s exact test or χ2 test depending on expected frequencies. Growth rates were compared using a mixed linear regression model with independent samples, accounting for the matched design. Results were considered statistically significant at p<0.05 (two tailed). All analyses were performed using R statistical software. Results Study population and baseline characteristics Between January 1997 and February 2024, we identified 90 patients with thoracic aortitis diagnosed on surgical pathology. Of these, 26 patients (28.9%) had at least two imaging studies at minimum 3-month intervals and met inclusion criteria. Three patients with aortitis were excluded due to inability to identify suitable matched controls (two with extreme ages: 36 and 91 years; one with combined ascending and arch replacement). From 1683 potential control patients who underwent TAA surgery, we included 42 controls after applying all matching criteria. The mean number of controls per case was 1.8 (median 2); 11 patients (48%) had only one matched control. Table 1 presents baseline characteristics. Both groups demonstrated female predominance (74% in cases, 60% in controls; p=0.37) with similar mean age of 73.7 and 73.5 years, respectively. No significant differences existed regarding body mass index (25.7 vs 26.2 kg/m², p=0.62), cardiovascular risk factors or cardiovascular history. Hypertension prevalence was comparable (74% of cases, 79% of controls; p=0.91), as was hypercholesterolaemia (57% vs 43%, p=0.43). Table 1Baseline characteristics of aortitis cases and degenerative controlsVariableAortitis (n=23)Controls (n=42)P value Demographics Female sex, n (%)17 (74%)25 (60%)0.374Age at surgery, years (mean±SD)73.773.50.875Body mass index, kg/m2 (mean±SD)25.726.20.615 Cardiovascular risk factors Current smoking, n (%)3 (13%)5 (12%)1Past smoking history, n (%)7 (30%)11 (26%)0.939No smoking history, n (%)13 (57%)26 (62%)0.873Family history of cardiovascular disease, n (%)4 (17%)10 (24%)0.754Prior cardiovascular disease, n (%)4 (17%)8 (19%)1 Coronary heart disease1 (25%)4 (50%)0.575 Stroke1 (25%)3 (38%)1 Lower extremity arterial disease2 (50%)1 (12%)0.236Hypertension, n (%)17 (74%)33 (79%)0.905Number of antihypertensive drugs (mean)1.41.50.539Preoperative antiplatelet therapy11 (48%)––Hypercholesterolaemia (%)13 (57%)18 (43%)0.426Diabetes mellitus, n (%)1 (4%)4 (10%)0.648History of aortic aneurysm3 (13%)3 (7%)0.657History of non-aortic aneurysm0 (0%)1 (2%)1 Inflammatory pathology subtype CIA 9 (39%)–– GCA 13 (57%)–– IgG4 related disease 1 (4%)–– Histological findings Granulomatous pattern, n (%)16 (70%)––Lymphoplasmacytic pattern, n (%)7 (30%)–– Anatomical data Aneurysm characteristics Ascending TAA, n (%)23 (100%)42 (100%)1Additional thoracic aortic aneurysm locations (arch, descending), n (%)3 (13%)0 (0%) <0.001 Ascending aortic maximal diameter at diagnosis, mm (mean)4949.30.846Ascending aortic maximal diameter at surgery, mm (mean)5654.60.237 Imaging surveillance before surgery Number of imaging studies, median (Q1–Q3)4 (3–5)4 (3–4)0.482 CT2 (1–2)2 (1–3)0.378 TTE2 (1–2)2 (1–3)0.750Interval between aortic aneurysm diagnosis and surgery in months, mean3241.90.483Interval between aortic aneurysm diagnosis and surgery in months, median (Q1–Q3)19 (9–32)18 (9–61)0.483 Preoperative aortic CT diameters Reassessed CT diameters12 (52%)26 (62%)Valsalva sinuses, mm (mean±SD)37.67±5.4540.75±7.130.052Sino tubular junction, mm (mean±SD)37.57±6.7840.09±6.060.14Ascending aorta, mm (mean±SD)55.39±3.353.19±7.210.11Aortic arch, mm (mean±SD)31.95±5.0534.34±6.42 0.044 Descending aorta, mm (mean±SD)32.45±9.8530.63±8.740.76 Surgical data Surgical indication Asymptomatic, critical size, n (%)22 (96%)13 (31%) <0.001 Symptomatic, n (%)1 (4%)29 (69%) <0.001 Surgical procedureSupracoronary tube graft, n (%)16 (70%)27 (64%)0.876Tirone David, n (%)1 (4%)1 (2%)1Bentall procedure, n (%)3 (13%)10 (24%)0.351Tube+arch, n (%)2 (9%)4 (10%)1 Associated procedure None23 (100%)18 (43%) <0.001 Atrial fibrillation ablation–3 (7%)–Aortic valve replacement–15 (36%)–Coronary artery bypass grafting–8 (19%)–Mitral valve replacement–3 (7%)–Tricuspid valve replacement–4 (10%)–Bold indicates p<0.05.CIA, clinically isolated aortitis; GCA, giant cell arteritis; Q1–Q3, interquartile 25 and 75; TAA, thoracic aortic aneurysm; TTE, transthoracic echocardiograpgy. Baseline characteristics of aortitis cases and degenerative controls Bold indicates p<0.05. CIA, clinically isolated aortitis; GCA, giant cell arteritis; Q1–Q3, interquartile 25 and 75; TAA, thoracic aortic aneurysm; TTE, transthoracic echocardiograpgy. Surgical and imaging characteristics All patients in both groups had ascending TAA. However, aneurysmal extension to the aortic arch and descending aorta or synchronous descending aneurysm occurred exclusively in the aortitis group (n=3, 13% vs 0%; p<0.001). Surgical procedures were also matched: supracoronary tube graft in 70% of cases and 64% of controls (p=0.88); Bentall procedure in 13% vs 24% (p=0.35). Control patients more frequently underwent concomitant cardiac interventional procedures (57% vs 0%; p<0.001) (valve replacement, atrial fibrillation ablation or coronary artery bypass grafting). The median number of preoperative imaging examinations was four in both groups (IQR 3–5 for cases, 3–4 for controls; p=0.48). The median interval between diagnosis and surgery was 19 months (Q1–Q3: 9–32) for cases and 18 months (Q1–Q3: 9–61) for controls (p=0.48). Mean baseline ascending aortic diameter was similar: 49.0 mm vs 49.3 mm (p=0.85). Surgical indications differed markedly. Aortitis patients were predominantly operated for asymptomatic aneurysms reaching critical size (96%, n=22), whereas controls were more often symptomatic (69%, n=29; p<0.001), primarily with dyspnoea (57%). Aortic regurgitation was present in 55% of cases. Despite different indications, mean aneurysmal diameter at surgery was similar: 56.0 mm in cases vs 54.6 mm in controls (p=0.24). Aortic diameters were centrally measured on CT in 52% of cases and 62% of controls. No significant difference was observed regarding diameters at the sinuses of Valsalva, sinotubular junction, ascending aorta or descending aorta (table 1). Mean aortic arch diameter was greater in controls (34.3 mm) compared with patients with aortitis (31.9 mm; p=0.044). Aortitis characteristics Among the 23 aortitis cases, GCA was the most common aetiology (n=13, 57%), followed by CIA (n=9, 39%) and IgG4-related disease (n=1, 4%); the latter was excluded from subgroup analysis to focus on differences between CIA and GCA. Among patients with GCA, 77% (n=10) had received corticosteroids at the time of surgery, and one had received immunosuppressive therapy. No patient with CIA had received corticosteroids or immunosuppressive treatment prior to surgery (p=0.002) as the diagnosis was established postoperatively on pathological examination. Preoperative CRP levels were available for 9 patients (69%), all within the GCA group; of these, 33% exhibited a persistent inflammatory syndrome (table 2). For patients with CIA, no preoperative inflammatory markers were available. Table 2Comparison of CIA and GCAVariableCIA (n=9)GCA (n=13)P value Demographics Female sex, n (%)6 (67%)11 (84%)0.643Age at surgery, years (mean±SD)71.273.40.233Body mass index, kg/m2 (mean±SD)26.125.40.680 Cardiovascular risk factors Current smoking, n (%)2 (22%)1 (7%)0.537Past smoking history, n (%)2 (22%)5 (38%)0.657No smoking history, n (%)5 (56%)8 (61%)1Family history of cardiovascular disease, n (%)2 (22%)2 (15%)1Prior cardiovascular disease, n (%)1 (11%)6 (46%)0.176 Coronary heart disease0 (0%)1 (7%)1 Stroke0 (0%)2 (14%)0.502 Lower extremity arterial disease0 (0%)1 (7%)1Hypertension, n (%)6 (67%)10 (76%)0.643Number of antihypertensive drugs (mean)1.71.20.535Preoperative antiplatelet therapy, n (%)3 (33%)8 (61%)0.400Hypercholesterolaemia, n (%)5 (56%)7 (54%)1Diabetes mellitus, n (%)0 (0%)1 (7%)1History of aortic aneurysm, n (%)1 (11%)2 (15%)1History of non-aortic aneurysm, n (%)0 (0%)0 (0%)1 Laboratory findings CRP, mg/L (mean)9.180.462Fibrinogen, g/L (mean)3.63.50.940Inflammatory syndrome (CRP>10 mg/L), n (%)1/2 (50%)2/6 (33%)1 Treatment data Corticosteroids, n (%)0 (0%)10 (77%) 0.002 Immunosuppressive therapy, n (%)0 (0%)1 (7%)1 Histological findings Granulomatous pattern, n (%)5 (56%)11 (79%)0.363Lymphoplasmacytic pattern, n (%)4 (44%)2 (15%)0.363 Anatomical data Aneurysm characteristics Thoracic ascending aorta, n (%)9 (100%)13 (100%)1Aortic arch, n (%)0 (0%)1 (7%)1Thoracic descending aorta, n (%)1 (11%)1 (7%)1Ascending aortic maximal diameter at diagnosis, mm (mean)50.647.90.204Ascending aortic maximal diameter at surgery, mm (mean)55.356.60.371 Imaging surveillance before aortic surgery Number of imaging studies, median (Q1–Q3)3 (2–4)4 (2–5)0.297 CT2 (1–2)2 (1–3)0.541 TTE1 (0–2)1 (1–3)0.601Interval between aortic aneurysm diagnosis and surgery in months, mean14.843.20.195Interval between aortic aneurysm diagnosis and surgery in months, median (Q1–Q3)11 (8–19)30 (11–49)0.195 Preoperative aortic CT diameters Reassessed diameters5 (55%)6 (46%)Valsalva sinuses, mm (mean±SD)37.7±5.337.6±60.91Sinotubular junction, mm (mean±SD)39.7±7.7036.0±7.70.26Ascending aorta, mm (mean±SD)55.7±1.9455.3±4.150.79Aortic arch, mm (mean±SD)32.2±4.3232.2±5.870.87Descending aorta, mm (mean±SD)33.1±11.132.6±9.471 Surgical data Surgical indication Asymptomatic critical size, n (%)9 (100%)12 (92%)1Symptomatic, n (%)0 (0%)1 (7%)1 Surgical procedure Supracoronary tube graft, n (%)4 (44%)12 (92%)0.065Tirone David, n (%)1 (11%)0 (0%)0.391Bentall procedure, n (%)3 (33%)0 (0%) 0.047 Tube+arch, n (%)1 (11%)1 (7%)1Bold indicates p<0.05.CIA, clinically isolated aortitis; CRP, C reactive protein; GCA, giant cell arteritis; Q1–Q3, interquartile 25 and 75; TTE, transthoracic echocardiograpgy. Comparison of CIA and GCA Bold indicates p<0.05. CIA, clinically isolated aortitis; CRP, C reactive protein; GCA, giant cell arteritis; Q1–Q3, interquartile 25 and 75; TTE, transthoracic echocardiograpgy. Histological examination revealed predominantly granulomatous inflammation (n=16, 70%) with lymphoplasmacytic pattern in 30% (n=7). Distribution did not differ significantly between CIA (56% granulomatous) and GCA (79% granulomatous; p=0.36). Aneurysm growth rate comparison The preoperative aneurysm growth rate was significantly higher in the aortitis group (figure 1A). The mean aortic diameter growth rate was 0.177±0.01 mm/month (2.12 mm/year) in inflammatory aortitis vs 0.039±0.02 mm/month (0.47 mm/year) in degenerative aneurysms. This represents approximately 4.5-fold faster growth in inflammatory cases, highly statistically significant (p<0.001). (A) Preoperative growth rates of thoracic aortic aneurysms: a comparison between inflammatory aortitis and degenerative controls using a linear regression model of aneurysm progression over time. (B) Preoperative thoracic aortic aneurysms growth rates by aortitis aetiology: a comparison between clinically isolated aortitis (CIA) and giant cell arteritis (GCA). Comparison between CIA and GCA revealed significant differences (figure 1B). Patients with CIA demonstrated substantially faster aneurysm growth (0.338±0.06 mm/month, 4.06 mm/year) compared with GCA (0.175±0.01 mm/month, 2.1 mm/year; p<0.01), representing a nearly twofold difference between these two diseases. No significant differences existed regarding age (71.2 vs 73.4 years, p=0.23), cardiovascular risk factors, baseline diameter (50.6 vs 47.9 mm, p=0.20) or ascending aortic diameter at surgery (55.3 vs 56.6 mm, p=0.37). Patients with CIA more frequently underwent Bentall procedure (33% vs 0%; p=0.047). Comparison of preoperative aortic diameters showed no significant difference between groups at the sinuses of Valsalva, sinotubular junction or any other thoracic aortic level. Discussion This case–control study presents the first comparison of preoperative aneurysm growth rates between inflammatory and degenerative TAA using matched controls. Our key finding—that aortitis accelerates growth by 4.5-fold—carries significant clinical and pathophysiological implications. Our control group growth rate of 0.47 mm/year aligns closely with a 2025 meta-analysis reporting degenerative TAA growth at 0.33 mm/year.13 This meta-analysis also documented rates of 0.45 mm/year for Marfan syndrome and 0.81 mm/year for Loeys-Dietz syndrome. Inflammatory aortitis growth rate of 2.12 mm/year substantially exceeds even hereditary connective tissue disorders, representing the fastest non-infectious TAA progression documented. Limited prior data support our findings. Kebed et al reported 1.3 mm/year in GCA-associated TAA,4 somewhat lower but similar magnitude. Quimson et al observed a non-significant trend towards faster CIA growth (2.9 mm/year) versus unmatched controls (−1.6 mm/year),5 but methodological limitations restrict interpretation. Our matched design provides substantially stronger evidence. Pathophysiological mechanisms Accelerated growth likely reflects distinct pathophysiology. Over aortitis group, we observed a lymphoplasmacytic pattern in seven cases (30%), consistent with reported frequencies (22–30%).61417 In GCA, the inflammatory cascade begins with dendritic cell antigen presentation activating CD4+ T lymphocytes, which differentiate into Th1 and Th17 subpopulations producing interferon-γ and interleukin 17. The inflammatory process begins in the adventitia, where an increase in the density of the vasa vasorum is observed. Circulating monocytes differentiate into macrophages that migrate to arterial intima and fuse into multinucleated giant cells.1 18 These cells secrete matrix metalloproteinases degrading elastin-rich extracellular matrix while inducing smooth muscle cell apoptosis. Medial smooth muscle cells migrate to the intima, transdifferentiate into myofibroblasts and proliferate, replacing elastic matrix with disorganised collagen and fibronectin.1 This fundamental alteration of biomechanical wall properties probably occurs more rapidly than gradual atherosclerotic remodelling. In inflammatory aortitis, the preferential involvement of the thoracic aorta compared with the abdominal aorta may reflect the distribution of the vasa vasorum, which gradually diminishes distally and thereby restricts inflammatory cell infiltration.1 The finding that 13% of aortitis patients had aneurysms in additional aortic locations—compared with none in the control group (p<0.001)—supports the presence of a more diffuse arteriopathy. Clinical phenotype and treatment implications The finding that patients with CIA demonstrated twofold faster preoperative aneurysm growth than patients with GCA (4.06 vs 2.1 mm/year) represents a novel observation. Patients with CIA also more frequently underwent Bentall procedure (33% vs 0%), suggesting more extensive aortic root involvement and possibly reflecting distinct topographic patterns. However, the nosological status of CIA remains debated. According to the CHCC2012 nomenclature, it cannot be determined whether CIA represents a truly distinct entity or a limited manifestation of GCA or Takayasu arteritis, and several studies have suggested that many patients with CIA may harbour subclinical GCA.19 20 In our cohort, 56% of patients with CIA had granulomatous inflammation indistinguishable from GCA, while 16–26% of patients with CIA eventually develop features of a systemic disease (predominantly GCA) during follow-up.6 14 Subtle differences in inflammatory mediators, genetic predisposition or antigen recognition could nonetheless influence disease behaviour.6 17 Therefore, the CIA versus GCA comparison in our study should be understood as a comparison based on clinical classification at the time of surgery rather than between definitively distinct pathological entities. The faster growth observed in CIA must also be interpreted in light of a major confounding factor: 77% of patients with GCA received corticosteroids preoperatively compared with 0% of patients with CIA. Treatment timing relative to aortic involvement onset is critical: GCA is usually diagnosed prior to surgery, allowing for earlier immunosuppressive therapy. Although there is no direct evidence that corticosteroids reduce aneurysm growth rate in GCA, immunosuppression has been shown to decrease the appearance of new vascular lesions,21 suggesting a potential attenuating effect on disease progression. In contrast, CIA typically presents as an isolated aneurysm, with diagnosis established only after surgery, precluding any preoperative treatment. The observed growth rate difference may therefore reflect, at least in part, the suppression of aortic wall inflammation by corticosteroids rather than an intrinsically faster growth rate in CIA. Separating the treatment effect from a potential pathophysiological difference is not possible in this observational design. Postoperative outcomes were not endpoints of the present study but in a multicentre study of 217 patients with noninfectious surgical thoracic aortitis, Espitia et al6 identified the main prognostic factors for adverse vascular outcomes, including aortic dissection at initial presentation and descending thoracic aorta involvement. Notably, there was no significant difference in the risk of vascular complications, second vascular procedure or mortality between CIA and other non-infectious aortitis patients. Furthermore, granulomatous aortitis was associated with a worse long-term prognosis compared with lymphoplasmacytic aortitis.15 In the present study, limited statistical power due to the small number of patients with lymphoplasmacytic aortitis precluded any definitive conclusion regarding a difference in aneurysm growth rate according to histological pattern. Selection bias inherent in our design—CIA diagnosis requires surgery and sufficient preoperative imaging—may have enriched our CIA cohort for rapidly progressive cases, whereas systemic disease patients benefit from systematic surveillance potentially detecting slower-growing aneurysms. However, this would emphasise rather than invalidate recognising rapid growth as a potential CIA indicator. Clinical implications and recommendations Our findings have immediate clinical relevance. Rapid TAA growth—particularly exceeding 3 mm/year—should prompt consideration of inflammatory aortitis, especially in women over 60 years, even without overt symptoms or elevated inflammatory markers. Such patients warrant comprehensive evaluation, including a systematic review for GCA symptoms (headache, jaw claudication, visual symptoms and polymyalgia), vascular imaging (CTA or MRI) to assess aortic wall thickening, [18F]-fluorodeoxyglucose positron emission tomography/CT if available and temporal artery biopsy if GCA suspected clinically.22 23 If aortitis is identified prior to surgery, the use of immunosuppressants or corticosteroids is considered on a case-by-case basis to minimise surgical complications, particularly difficulties in suturing an inflamed aortic wall. Faster growth in CIA suggests particularly intensive postoperative surveillance, as these patients show high rates of new aortic complications (47% develop subsequent aneurysms vs 7% of degenerative controls) and reoperation (40–46% in major series).6 14 24 Whether empiric postoperative immunosuppression could improve CIA outcomes remains an open question requiring prospective investigation.6 14 Strengths and limitations Study strengths include a rigorous matched case–control design, standardised measurement protocols with 58% of scans centralised review, comprehensive clinical data from a tertiary referral centre with recognised expertise, long preoperative imaging follow-up (median 18–19 months) and robust statistical methodology using mixed linear regression validated in previous aneurysm growth studies. Important limitations warrant consideration. The retrospective single-centre design and sample size limit subgroup analyses and generalisability. Matching difficulties in order to have a large number of controls arose from population differences: controls were predominantly younger men with associated cardiac pathology requiring complex procedures, whereas aortitis patients were older women with isolated ascending disease requiring simpler operations. The shorter observation period in CIA (median 11 months) compared with GCA (median 30 months) may raise concerns regarding the reliability of growth rate estimation. However, this shorter surveillance period is itself a consequence of the faster aneurysm growth, leading to earlier achievement of surgical criteria. Moreover, the number of imaging data points before surgery was comparable (median 3 vs 4), providing reasonable measurement density for linear regression estimation. Nevertheless, the growth rate in CIA should be interpreted with appropriate caution pending validation in larger cohorts with longer follow-up. Furthermore, the control group includes a significant proportion of these slow-progressing cases. Selection bias inevitably affects surgical cohorts—patients dying before reaching operative diameter, declining surgery or deemed unsuitable were excluded. However, no factors suggest differential bias between groups. Conclusion This matched case–control study demonstrates that inflammatory aortitis is associated with 4.5-fold faster preoperative TAA growth compared with degenerative aneurysms (2.1 vs 0.5 mm/year). These findings establish inflammatory aortitis as the fastest non-infectious cause of TAA progression documented. Among inflammatory aetiologies, preoperatively undiagnosed CIA shows approximately twofold faster growth than mostly corticosteroid-treated GCA (4.1 vs 2.1 mm/year), although this design does not allow distinguish between distinct pathophysiological mechanisms and a treatment effect. Rapid TAA growth should prompt clinical suspicion of underlying inflammatory aortitis, particularly in older women, warranting comprehensive evaluation even without classical inflammatory symptoms or biomarkers. Prospective multicentre studies are warranted to validate our findings, elucidate pathophysiology of accelerated inflammatory aneurysm growth and optimise management algorithms for this high-risk population.